AstraZeneca stays on course to challenge Alnylam with 66-week rare disease data

AstraZeneca and Ionis Pharmaceuticals have breezed past another marker on the route to approval of eplontersen, revealing that the challenger to Alnylam’s Amvuttra and Onpattro improved outcomes in a rare disease out to 66 weeks.